- Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
- Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
- Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
- Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
- Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
- Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
- Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
- Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
- Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
More ▼
Key statistics
On Friday, Catalyst Pharmaceuticals Inc (CPRX:NAQ) closed at 16.49, -5.74% below its 52-week high of 17.50, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.55 |
---|---|
High | 16.85 |
Low | 16.32 |
Bid | 16.35 |
Offer | 16.77 |
Previous close | 16.40 |
Average volume | 1.22m |
---|---|
Shares outstanding | 118.12m |
Free float | 110.78m |
P/E (TTM) | 30.46 |
Market cap | 1.94bn USD |
EPS (TTM) | 0.5384 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼